

Referenslista till Ingemar Peterssons föredrag "Reumatiska sjukdomar - vem drabbas och hur?" på Forskningens dag 2013.

Leden I, Svensson B, Harding B, Nuorala E, Liden K, Gotherstrom A. *Paleopathology can be beneficial for current rheumatologic research*. Lakartidningen. 2002 Mar7;99(10):1060.

Kjeken I, Ziegler C, Skrolsvik J, Bagge J, Smedslund G, Tovik A, Petersson IF et al. *How to develop patient-centered research: some perspectives based on surveys among people with rheumatic diseases in Scandinavia*. Phys Ther. 2010 Mar;90(3):450-60.

Hagel S, Petersson IF, Bremander A, Lindqvist E, Bergknut C, Englund M. *Trends in the first decade of 21st century healthcare utilisation in a rheumatoid arthritis cohort compared with the general population*. Ann Rheum Dis. 2013 Dec 8;72(7):1212-6.

Gulfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. *Rapid and sustained health utility gain in anti-tumour necrosis factor-treated inflammatory arthritis: observational data during 7 years in southern Sweden*. Ann Rheum Dis. 2009 Feb;69(2):352-7.

Olofsson T, Englund M, Saxne T, Joud A, Jacobsson LT, Geborek P, Petersson IF. *Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study*. Ann Rheum Dis. 2010 Dec;69(12):2131-6.

Hekmat K, Jacobsson L, Nilsson JÅ, Petersson IF, Robertsson O, Garellick G, et al. *Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis – results from a well defined population in south Sweden*. Arthritis Research & Therapy. 2011;13(2):R67.

van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. *Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial*. Lancet. 2009 Aug 8;374(9688):459-66.

Simonsson M, Bergman S, Jacobsson LT, Petersson IF, Svensson B. *The prevalence of rheumatoid arthritis in Sweden*. Scand J Rheumatol. 1999;28(6):340-3.

Englund M, Joud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. *Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics*. Rheumatology (Oxford). 2010 Aug;49(8):1563-9.

Haglund E, Bremander AB, Petersson IF, Strombeck B, Bergman S, Jacobsson LT, et al. *Prevalence of spondyloarthritis and its subtypes in southern Sweden*. Ann Rheum Dis. 2011 Feb 2;70(6):943-8.

van Vollenhoven RF, Geborek P, Albertsson K, Forslind K, Ernestam S, Petersson I. F., Chatzidionysiou A, Bratt J, for the SWEFOT study group. *Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial*. Lancet. 2012 May 5;379(9827):1712-20. Epub 2012 Mar 29

Eriksson J, Neovius M, Bratt J, Petersson IF, van Vollenhoven RF, Geborek P & Ernestam S. *Biologic versus Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis: a randomized trial*. JAMA Intern Med. 2013 Jul 1. doi: 10.1001/jamainternmed.2013.7801.